7-Chloro-4H-pyrido[4,3-b][1,4]oxazin-3-one | 1206977-63-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 7-Chloro-4H-pyrido[4,3-b][1,4]oxazin-3-one
• CAS: 1206977-63-0
• 化学式: C₇H₅ClN₂O₂
• 分子量: 184.58
• InChiKey: XSXCAGMINNETDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] GLYCOSIDASE INHIBITORS<br/>[FR] INHIBITEURS DE GLYCOSIDASES
  申请人：ASCENEURON S A

  公开号：WO2017144633A1

  公开（公告）日：2017-08-31

  Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

  式(I)中A、R、W、Q、n和m的含义如权利要求书所述，可用于治疗tau病和阿尔茨海默病。
• [EN] FUSED IMIDAZOLE COMPOUNDS<br/>[FR] COMPOSÉS D'IMIDAZOLE CONDENSÉS
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2015115673A1

  公开（公告）日：2015-08-06

  The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

  本发明提供了由式(I)表示的化合物，其药学上可接受的盐，N-氧化物，溶剂合物或前药（其中字符如描述中所定义）。由式(I)表示的化合物对γ-氨基丁酸A受体亚单位α5（GABAA α5）具有亲和力和选择性，并作为GABAA α5负向变构调节剂（GABAA α5 NAM）发挥作用，因此它们在预防和/或治疗与GABAA α5相关的疾病，如阿尔茨海默病中是有用的。
• Fused imidazole compounds
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US10016439B2

  公开（公告）日：2018-07-10

  The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compounds represented by formula (I) have affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 (GABAA α5) and act as GABAA α5 negative allosteric modulators (GABAA α5 NAM), so that they are useful in the prevention and/or treatment of diseases which are related to the GABAA α5 such as Alzheimer's disease.

  本发明提供了式(I)代表的化合物、其药学上可接受的盐、其N-氧化物、其溶液剂或其原药（其中特征如描述中所定义）。式（I）代表的化合物对γ-氨基丁酸A受体亚基α5（GABAA α5）具有亲和性和选择性，可作为GABAA α5负异位调节剂（GABAA α5 NAM），因此可用于预防和/或治疗与GABAA α5相关的疾病，如阿尔茨海默病。
• FUSED IMIDAZOLE COMPOUNDS
  申请人：ONO Pharmaceutical Co., Ltd.

  公开号：EP3099672A1

  公开（公告）日：2016-12-07
• GLYCOSIDASE INHIBITORS
  申请人：Asceneuron SA

  公开号：EP3419971A1

  公开（公告）日：2019-01-02